These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 24722449)

  • 21. Human recombinant erythropoietin reduces sensorimotor dysfunction and cognitive impairment in rat models of chronic kidney disease.
    Reza-Zaldívar EE; Sandoval-Avila S; Gutiérrez-Mercado YK; Vázquez-Méndez E; Canales-Aguirre AA; Esquivel-Solís H; Gómez-Pinedo U; Márquez-Aguirre AL
    Neurologia (Engl Ed); 2020 Apr; 35(3):147-154. PubMed ID: 29132915
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Uremic Toxins Affect Erythropoiesis during the Course of Chronic Kidney Disease: A Review.
    Hamza E; Metzinger L; Metzinger-Le Meuth V
    Cells; 2020 Sep; 9(9):. PubMed ID: 32899941
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Anemia in chronic kidney disease--reasons and treatment].
    Dylewska M; Wieliczko M
    Wiad Lek; 2014; 67(3):410-2. PubMed ID: 25782200
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Down-Regulation of Cardiac Erythropoietin Receptor and its Downstream Activated Signal Transducer Phospho-STAT-5 in a Rat Model of Chronic Kidney Disease.
    Hertzberg-Bigelman E; Barashi R; Levy R; Cohen L; Ben-Shoshan J; Keren G; Entin-Meer M
    Isr Med Assoc J; 2016 Jun; 18(6):326-30. PubMed ID: 27468524
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of achieved hemoglobin level on renal outcome in non-dialysis chronic kidney disease (CKD) patients receiving epoetin beta pegol: MIRcerA CLinical Evidence on Renal Survival in CKD patients with renal anemia (MIRACLE-CKD Study).
    Hayashi T; Uemura Y; Kumagai M; Kimpara M; Kanno H; Ohashi Y;
    Clin Exp Nephrol; 2019 Mar; 23(3):349-361. PubMed ID: 30291472
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Epoetin beta pegol for treatment of anemia ameliorates deterioration of erythrocyte quality associated with chronic kidney disease.
    Aizawa K; Kawasaki R; Tashiro Y; Shimonaka Y; Hirata M
    BMC Nephrol; 2018 Jan; 19(1):19. PubMed ID: 29374477
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of anemia with erythropoietin-stimulating agents in kidney transplant recipients and chronic kidney disease-another drawback of immunosuppression?
    Malyszko J; Glowinska I; Mysliwiec M
    Transplant Proc; 2012 Dec; 44(10):3013-6. PubMed ID: 23195016
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Low erythropoietin levels predict faster renal function decline in diabetic patients with anemia: a prospective cohort study.
    Fujita Y; Doi Y; Hamano T; Hatazaki M; Umayahara Y; Isaka Y; Tsubakihara Y
    Sci Rep; 2019 Oct; 9(1):14871. PubMed ID: 31619722
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Long-acting erythropoetin efficacy in the treatment of nephrogenic anemia in patients with chronic kidney disease during predialysis stage].
    Milovanov IuS; Milovanova LIu
    Ter Arkh; 2012; 84(6):48-52. PubMed ID: 22997919
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Administration of iron in renal anemia.
    Poskurica M; Petrović D; Poskurica M
    Vojnosanit Pregl; 2015 Apr; 72(4):361-7. PubMed ID: 26040183
    [No Abstract]   [Full Text] [Related]  

  • 31. Methoxy Polyethylene Glycol-Epoetin Beta as a Novel Erythropoiesis Stimulating Agent with Possible Nephroprotective and Cardiovascular Protective Effects in Non-Dialysis Chronic Kidney Disease Patients.
    Piotr B; Mariusz S; Jacek R
    Curr Pharm Biotechnol; 2017; 18(4):303-308. PubMed ID: 28137221
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Resistance to Recombinant Human Erythropoietin Therapy in a Rat Model of Chronic Kidney Disease Associated Anemia.
    Garrido P; Ribeiro S; Fernandes J; Vala H; Rocha-Pereira P; Bronze-da-Rocha E; Belo L; Costa E; Santos-Silva A; Reis F
    Int J Mol Sci; 2015 Dec; 17(1):. PubMed ID: 26712750
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Protocol of a randomized controlled trial of an erythropoietin stimulating agent decision aid for anemia treatment in kidney disease.
    Beach LB; Wild M; Ramachandran G; Ikizler HO; Cavanaugh KL
    BMC Nephrol; 2016 Jul; 17(1):86. PubMed ID: 27430294
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Response to erythropoietin in pediatric patients with chronic kidney disease: insights from an in vitro bioassay.
    Gavish R; Watad S; Ben-Califa N; Goldberg OJ; Haskin O; Davidovits M; Koren G; Falush Y; Neumann D; Krause I
    Pediatr Nephrol; 2018 Nov; 33(11):2123-2129. PubMed ID: 30030607
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cytomegalovirus esophagitis with symptoms of gastroesophageal reflux disease in a kidney transplant recipient.
    Chen YJ; Huang HC; Chen TC; Cheng HT
    Kaohsiung J Med Sci; 2020 Oct; 36(10):859-860. PubMed ID: 32671960
    [No Abstract]   [Full Text] [Related]  

  • 36. TP0463518, a novel inhibitor for hypoxia-inducible factor prolyl hydroxylases, increases erythropoietin in rodents and monkeys with a good pharmacokinetics-pharmacodynamics correlation.
    Kato S; Takayama N; Takano H; Koretsune H; Koizumi C; Kunioka EI; Uchida S; Takahashi T; Yamamoto K
    Eur J Pharmacol; 2018 Nov; 838():138-144. PubMed ID: 30179610
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Iron isotopic composition of blood serum in anemia of chronic kidney disease.
    Anoshkina Y; Costas-Rodríguez M; Speeckaert M; Van Biesen W; Delanghe J; Vanhaecke F
    Metallomics; 2017 May; 9(5):517-524. PubMed ID: 28417130
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anaemia in diabetic renal failure: is there a role for early erythropoietin treatment in preventing cardiovascular mortality?
    Abaterusso C; Pertica N; Lupo A; Ortalda V; Gambaro G
    Diabetes Obes Metab; 2008 Sep; 10(10):843-9. PubMed ID: 18093210
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hemoglobin stability in patients with anemia, CKD, and type 2 diabetes: an analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) placebo arm.
    Skali H; Lin J; Pfeffer MA; Chen CY; Cooper ME; McMurray JJ; Nissenson AR; Remuzzi G; Rossert J; Parfrey PS; Scott-Douglas NW; Singh AK; Toto R; Uno H; Ivanovich P
    Am J Kidney Dis; 2013 Feb; 61(2):238-46. PubMed ID: 23159232
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anemia of chronic kidney disease: Treat it, but not too aggressively.
    Nakhoul G; Simon JF
    Cleve Clin J Med; 2016 Aug; 83(8):613-24. PubMed ID: 27505883
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.